TD Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$538K Buy
+9,400
New +$515K ﹤0.01% 1171
2025
Q4
Sell
-16,605
Closed -$899K 1245
2025
Q3
$899K Sell
16,605
-636
-4% -$36.4K ﹤0.01% 1108
2025
Q2
$948K Sell
17,241
-17,881
-51% -$1.05M ﹤0.01% 1069
2025
Q1
$2.48M Sell
35,122
-59,008
-63% -$3.97M ﹤0.01% 910
2024
Q4
$6.19M Sell
94,130
-9,125
-9% -$611K 0.01% 754
2024
Q3
$7.29M Sell
103,255
-40,642
-28% -$3.4M 0.01% 703
2024
Q2
$11.8M Sell
143,897
-14,724
-9% -$1.23M 0.01% 597
2024
Q1
$13.9M Sell
158,621
-32,409
-17% -$2.9M 0.01% 566
2023
Q4
$18.4M Buy
191,030
+17,858
+10% +$1.58M 0.02% 496
2023
Q3
$15.3M Buy
173,172
+72,742
+72% +$6.47M 0.02% 494
2023
Q2
$8.71M Sell
100,430
-2,839
-3% -$267K 0.01% 628
2023
Q1
$10M Buy
103,269
+23,768
+30% +$2.46M 0.01% 605
2022
Q4
$8.23M Buy
79,501
+24,485
+45% +$2.3M 0.01% 636
2022
Q3
$4.68M Buy
55,016
+5,551
+11% +$494K 0.01% 774
2022
Q2
$4.1M Sell
49,465
-6,158
-11% -$490K ﹤0.01% 815
2022
Q1
$4.29M Buy
55,623
+27,485
+98% +$2.3M ﹤0.01% 860
2021
Q4
$2.49M Sell
28,138
-1,007
-3% -$83.1K ﹤0.01% 1081
2021
Q3
$2.25M Buy
29,145
+56
+0.2% +$4.42K ﹤0.01% 1052
2021
Q2
$2.23M Sell
29,089
-35,000
-55% -$2.77M ﹤0.01% 1065
2021
Q1
$4.84M Sell
64,089
-369
-0.6% -$30.1K 0.01% 837
2020
Q4
$5.65M Buy
64,458
+403
+0.6% +$32K 0.01% 757
2020
Q3
$4.87M Sell
64,055
-7,111
-10% -$719K 0.01% 712
2020
Q2
$8.78M Buy
71,166
+2,472
+4% +$246K 0.01% 541
2020
Q1
$5.8M Sell
68,694
-19,200
-22% -$1.65M 0.01% 591
2019
Q4
$7.43M Buy
87,894
+3,316
+4% +$250K 0.01% 630
2019
Q3
$5.7M Buy
84,578
+5,300
+7% +$408K 0.01% 654
2019
Q2
$6.79M Sell
79,278
-10,333
-12% -$884K 0.01% 618
2019
Q1
$7.96M Buy
89,611
+8,051
+10% +$746K 0.01% 574
2018
Q4
$6.95M Sell
81,560
-6,886
-8% -$655K 0.01% 569
2018
Q3
$8.58M Buy
88,446
+540
+0.6% +$53.9K 0.01% 578
2018
Q2
$8.28M Buy
87,906
+14,107
+19% +$1.24M 0.01% 566
2018
Q1
$5.98M Sell
73,799
-4,222
-5% -$362K 0.01% 635
2017
Q4
$6.96M Buy
78,021
+3,397
+5% +$295K 0.01% 607
2017
Q3
$6.95M Buy
74,624
+11,465
+18% +$1.01M 0.01% 591
2017
Q2
$5.74M Buy
63,159
+127
+0.2% +$11.6K 0.01% 652
2017
Q1
$5.53M Buy
63,032
+13,365
+27% +$1.19M 0.01% 661
2016
Q4
$4.11M Buy
49,667
+402
+0.8% +$34.6K 0.01% 722
2016
Q3
$4.56M Buy
49,265
+342
+0.7% +$32.2K 0.01% 723
2016
Q2
$3.81M Sell
48,923
-42,662
-47% -$3.63M 0.01% 749
2016
Q1
$7.55M Sell
91,585
-13,798
-13% -$1.12M 0.01% 557
2015
Q4
$11M Buy
105,383
+310
+0.3% +$32.4K 0.02% 464
2015
Q3
$11.1M Buy
105,073
+6,656
+7% +$889K 0.02% 436
2015
Q2
$13.5M Sell
98,417
-3,600
-4% -$446K 0.02% 439
2015
Q1
$12.7M Buy
102,017
+44,016
+76% +$4.66M 0.02% 437
2014
Q4
$5.24M Buy
58,001
+1,601
+3% +$133K 0.01% 650
2014
Q3
$4.07M Sell
56,400
-1,800
-3% -$118K 0.01% 691
2014
Q2
$3.62M Sell
58,200
-2,800
-5% -$169K 0.01% 733
2014
Q1
$4.16M Sell
61,000
-5,000
-8% -$368K 0.01% 692
2013
Q4
$4.64M Sell
66,000
-600
-0.9% -$40.7K 0.01% 646
2013
Q3
$4.81M Sell
66,600
-4,300
-6% -$286K 0.01% 612
2013
Q2
$3.96M Buy
+70,900
New +$4.42M 0.01% 639

Other funds holding BMRN

TD Asset Management's BMRN Position: Q2 2026 in Review

TD Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 9,400 shares worth $538K. The stake represents ﹤0.01% of the portfolio and ranks #1171 among its holdings. This is a return to the name: TD Asset Management previously reported a position in BMRN as recently as Q3 2025.

TD Asset Management first reported a position in BMRN in Q2 2013 and has held it in 51 quarters since. The position peaked at $18.4M in Q4 2023. 413 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • TD Asset Management held 9,400 shares of BioMarin Pharmaceuticals worth $538K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new TD Asset Management position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1171 holding.
  • TD Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • TD Asset Management's BioMarin Pharmaceuticals position peaked at $18.4M in Q4 2023.
  • 413 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.